Skip to content

Evaluation of Acipimox for the Treatment in patients with abnomal ALT non-alcoholic fatty liver disease :A Prospective, Randomized, Controlled clinical trial

Evaluation of Acipimox for the Treatment in patients with abnomal ALT non-alcoholic fatty liver disease: A Prospective, Randomized, Controlled clinical trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-17012342
Enrollment
Unknown
Registered
2017-08-11
Start date
2017-08-20
Completion date
Unknown
Last updated
2017-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nonalcoholic Fatty Liver Disease

Interventions

Acipimox treatment group:acipimox 0.25 tid po
lifestyle intervention group:Lifestyle Counselling

Sponsors

the Affiliated hospital of Southwest Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 70 Years

Inclusion criteria

Inclusion criteria: The patients who is diagnosed non-alcoholic fatty liver disease-prospective in endocrinology in hospital or outpatient through abdminal ultrasound, CT, MRA, aged from 14 to 70-year-old male or famale, before join in did not receive more than 3 consecutive days or total not more than 7 consecutive days any kind of reduced triglycerides of drug treatment, and volunteer to join this clinical research.

Exclusion criteria

Exclusion criteria: 1. a history of alcohol intake greater than men >140g/week,woman>70g/week; 2. evidence of viral hepatitis, drug-induced liver disease, autoimmune liver disease, schistosomiasis liver disease,hereditary liver disease and so on; 3. parenteral nutrition,inflammatory bowel disease,Cushing's syndrome,hypopituitarism; 4. Thyroid disease,including hyperthyroidism,hypothyroidism; 5. Combined with the special cases o serious diorder,such as T1DM, special type of diabetes, GDM, the acute complications of T2DM, serious infection, end-stage renal disease,blood disease and so on; 6. gestation,suffering from malignant tumor in 2 years, suffering from acute cerebrovascular accident in half year.

Design outcomes

Primary

MeasureTime frame
height;weight;waistline;hipline;blood pressure;blood routine examination;liver function;blood lipids;renal function;HbA1c;FBG;PPG;Fins;FFA;

Countries

China

Contacts

Public ContactXu Ling

the Affiliated hospital of Southwest Medical University

764684471@qq.com+86 18008215025

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026